Elekta has launched the artificial intelligence (AI)-powered linear accelerator (linac), named Evo, offering advanced cancer treatment options.

The CT-Linac is equipped with high-definition imaging and is designed to deliver both offline and online adaptive radiation therapy, as well as enhanced standard image-guided radiation therapy treatments.

Elekta’s Evo aims to achieve more accurate targeting, diminish side effects, and enhance the quality of life for cancer patients.

Central to Evo's functionality is its sophisticated AI technology and anatomy-specific algorithms.

The system features high-definition imaging component, Iris, to enable clinicians to precisely identify and visualise treatment areas.

Complementing the launch of Evo, Elekta has introduced a new extension to its comprehensive software suite, Elekta ONE Planning, powered by MIM.

This solution offers distributed treatment planning, accelerated dose calculation, and AI-driven automation in contouring and dose planning.

Notably, Elekta ONE Planning is compatible with both Elekta and non-Elekta equipment, including proton therapy systems, positioning it as a highly competitive offering in the market.

Elekta’ Linac and Software Solutions president Maurits Wolleswinkel said: “Evo is an incredibly versatile linac that – in the era of increasingly stretched resources – will give our customers the freedom to adopt new technologies at their own pace.

“With the recently announced treatment planning enhancements to our Elekta ONE software suite, we now have a comprehensive offering for increased personalization as well as versatility that can take radiation therapy to the next level.”

In a separate announcement, Elekta signed an agreement to acquire Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent portfolio.

The acquisition is expected to strengthen Elekta’s position in treatment planning.

Under the agreement, Philips’ patent portfolio in the radiation oncology treatment planning domain will be transferred to Elekta.